Achaogen 30% pullback since last month overdone, says William Blair
After attending the company's investor event, William Blair analyst Y. Katherine Xu says shares of Achaogen at current levels offer an attractive entry opportunity. While most of the Street has modeled the use of Zemdri in carbapenem-resistant enterobacteriaceae, extended-spectrum beta-lactamases-producing bacteria is also a major target and represents a much larger population, Xu tells investors in a research note. Further, she believes physicians are and will be comfortable to use Zemdri off-label in blood stream infections and pneumonia. The analyst views the 30% pullback in Achaogen shares since the complicated urinary tract infections approval last month as overdone and thinks her $23 fair value estimate could prove conservative. Xu keeps an Outperform rating on Achaogen.